Table 4 Multivariate analyses for predicting factors of primary outcome events.

From: Prognostic effect of high-density lipoprotein cholesterol level in patients with atherosclerotic cardiovascular disease under statin treatment

Parameter

Hazard ratio

95% CI

p value

Age

1.02

1.00–1.04

0.03

Male (vs. female)

0.71

0.42–1.20

0.20

History hypertension

0.97

0.62–1.52

0.91

History of diabetes mellitus

1.36

0.92–2.01

0.13

History of heart failure

2.08

1.30–3.31

 < 0.01

History of myocardial infarction

1.73

0.94–3.22

0.08

Previous coronary/peripheral intervention

1.16

0.76–1.75

0.49

History of ischemic stroke/TIA

1.54

0.90–2.62

0.12

Cigarette smoking history

1.85

1.15–2.97

0.01

Statin intensity (vs. Moderate intensity)

Low intensity

0.91

0.53–1.56

0.72

High intensity

0.55

0.17–1.73

0.30

Anti-platelets therapy

1.19

0.59–2.39

0.63

ARB/ACEI

1.25

0.83–1.88

0.28

Beta-blocker

0.56

0.37–0.82

 < 0.01

BMI (vs. BMI ≥ 27.5)

BMI < 23

1.45

0.84–2.49

0.18

23 ≤ BMI < 27.5

0.88

0.55–1.41

0.61

eGFR (vs. eGFR > 60 ml/min/1.73m2)

30 < eGFR ≤ 60

1.44

0.92–2.25

0.11

eGFR ≤ 30

4.33

2.20–8.50

 < 0.0001

Normal HDL-C level (vs. Low HDL-C)

0.83

0.56–1.23

0.35

  1. *Abbreviations are the same as the Table 1. eGFR, estimated glomerular filtration rate.
Back to article page